US20020161048A1 - Glycine substitutes and precursors for treating a psychosis - Google Patents

Glycine substitutes and precursors for treating a psychosis Download PDF

Info

Publication number
US20020161048A1
US20020161048A1 US10/059,362 US5936202A US2002161048A1 US 20020161048 A1 US20020161048 A1 US 20020161048A1 US 5936202 A US5936202 A US 5936202A US 2002161048 A1 US2002161048 A1 US 2002161048A1
Authority
US
United States
Prior art keywords
glycine
schizophrenia
treatment
nmda
cycloserine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/059,362
Inventor
Daniel Javitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glytech Inc
Original Assignee
Glytech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/759,714 external-priority patent/US5854286A/en
Application filed by Glytech Inc filed Critical Glytech Inc
Priority to US10/059,362 priority Critical patent/US20020161048A1/en
Publication of US20020161048A1 publication Critical patent/US20020161048A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • NMDA receptor activity is also modulated by the amino acid glycine which binds to a selective modulatory site that is an integral component of the NMDA receptor complex.
  • U.S. Pat. No. 5,854,286 discloses the use of orally administered glycine, in dietary quantities, for the treatment of schizophrenia.
  • Glycine is considered a full agonist at the NMDA-associated glycine binding site (McBain et al., 1989).
  • the clinical findings with glycine detailed in the prior patents U.S. Pat. No. 5,854,286 and U.S. Pat. No. 5,837,730 applications therefore, provided the first evidence that glycine-site full agonists are effective in the treatment of schizophrenia.
  • D-Serine like glycine, is present in brain in high concentration and may serve as an endogenous ligand for the glycine binding site of the NMDA receptor complex (Schell et al., 1995).
  • D-serine along with use of other agents that might substitute for glycine at the glycine site of the NMDA receptor complex, was disclosed in the above noted U.S. patents and in Provisional application No. 60/008361 filed Dec. 1, 1995.
  • Partial agonists bind to the same site as full agonists (i.e., glycine recognition site of the NMDA receptor complex), but potentiate channel opening only to a much smaller percent (typically 40-70% of the activation seen with full agonists, McBain et al., 1989).
  • a second potential approach to augmentation of NMDA receptor-mediated neurotransmission is the administration of agents that inhibit glycine transporters in brain, thereby preventing glycine removal from active sites within CNS. It has been known for many years that the brain contains active transport systems for glycine that may regulate brain levels (Debler and Lajtha, 1987; D'Souza, 1995). More recent studies demonstrated that glycine transporters are differentially expressed in different brain region (Liu et al, 1993; Zafra et al., 1995) and may be co-localized with NMDA receptors (Smith et al., 1992).
  • U.S. Pat. No. 5,837,730 to the current inventor provided the first evidence that an identified glycine transport inhibitor, glycyldodecylamide (GDA), was able to exert glycine-like, anti-PCP behavioral effects in rodents, and thus the first evidence that glycine transport inhibitors should exert glycine-like amelioration of negative and cognitive symptoms in schizophrenia.
  • GDA glycyldodecylamide
  • data were presented from a series of three compounds demonstrating appropriate rank order of potency of these compounds in producing glycine-like behavioral effects in rodents.
  • amino acids, prodrugs or polypeptides which serve as precursors for other full glycine agonists in CNS can be employed. This may be accomplished by microencapsulation of glycine, for example using liposomes, for delivery to CNS, or by construction of polyglycine or polyserine vectors incorporating a CNS targeted moiety chosen to encourage penetration into CNS.
  • the present inventor can now demonstrate that the ability of glycine transport inhibitors to reverse PCP-induced behavioral effects correlates significantly with their ability to inhibit glycine transport in vitro, supporting the discovery that such agents exert their glycine-like behavioral effects by blocking brain glycine transport.
  • a number of glycylakylamides are tested herein (Study 2).
  • Study 1 Relative effectiveness of a glycine binding site full agonist (glycine) and partial agonist (D-cycloserine) in the treatment of schizophrenia.
  • NMDA receptor activation is regulated not only by glutamate but also by glycine, which mediates its action at a strychnine-insensitive binding site associated with the NMDA receptor complex. Glycinergic agents, therefore, may be therapeutically beneficial in schizophrenia.
  • Glycine is a naturally occurring amino acid and a normal dietary constituent. Glycine acts as a full agonist at the NMDA-associated glycine binding site, but must be given at large (>30 g/day) doses because of its poor permeability across the blood brain barrier.
  • D -Cycloserine is an anti-tubercular drug that also functions as a partial agonist at the NMDA-associated glycine site. D -Cycloserine readily crosses the blood-brain barrier.
  • D-cycloserine is only 40% as effective as glycine in potentiating NMDA receptor-mediated neurotransmission.
  • D -cycloserine may act as a functional glycine antagonist.
  • glycine the present inventor
  • D -cycloserine D'Souza et al., 1995
  • the baseline negative symptom score for the 7 subjects was 39.0 ⁇ 6.6.
  • negative symptoms increased by 0.1 ⁇ 1.7 points during treatment with placebo.
  • GLYT2 glycine type 2 transporters
  • GLYT1 type 1 transporters
  • GLYT1 type 1 transporters
  • GLYT1 are co-localized with NMDA receptors in forebrain and hippocampus, and may serve to maintain low intrasynaptic glycine levels specifically in the local region around NMDA receptors. It is possible, therefore, that inhibition of GLYT1 transporters would lead to elevations of glycine levels in the immediate vicinity of NMDA receptors and augmentation of NMDA receptor-mediated neurotransmission without requiring administration of exogenous glycine.
  • Glycinearnide derivatives were synthesized in house according to the approach of Toth et al (1986).
  • the specific agents used for study were glycylhexylamide (G6A), glycyloctylamide (G8A), glycyldecylamide (G10A), glycylundecylamide (G11A) and glycyltriscadecylamide (G13A).
  • Synaptosomal P 2 fractions were prepared from cerebral cortex+hippocampus of Sprague-Dawley rats (200-250 g). Brain tissue was homogenized in 0.32 M sucrose in Tris-HCl buffer (pH 7.4), and centrifuged at 1,000 ⁇ g for 10 min at 4° C. in a Sorvall 5C centrifuge. The supernatant was then centrifuged at 14,000 ⁇ g for 10 min and the pellet resuspended in artificial CSF having the following composition (mM): NaCl, 125; KCl, 3; MgSO 4 , 1.2; CaCl 2 , 1.2; NaH 2 PO 4 , 1; NaHCO 3 , 22; glucose, 10.
  • mM composition
  • Homogenate was aerated with 95% 0 2 /5% CO 2 until use. 1 ml aliquots of homogenate were preincubated with specific concentrations of glycineamide derivatives, following which incubation was initiated by the addition of 10 ⁇ l of 10 ⁇ M [ 3 H]glycine (DuPont/NEN or Sigma, spec. act. ⁇ 45 Ci/mmol) to obtain a final concentration of 100 nM. Nonspecific binding was determined in the presence of 10 mM sarcosine. Following 5 min, incubation was terminated by filtration under reduced pressure using a Brandel 24-well cell harvester and Whatman GF-B filters. Radioactivity was determined by scintillation counter with approximate efficiency of 50%.
  • agents which should be useful for treating schizophrenia through inhibition of glycine transport include other glycylakylamides in which the alkyl group contains 3 to 30 carbon atoms, and structures containing branched, cyclic or polycyclic side chains.

Abstract

Process for treating psychosis such as schizophrenia using glycine-site fall agonists or a precursor thereof.

Description

    RELATED APPLICATIONS
  • This application is a continuation-in-part application of prior application Ser. No. 09/212,273 filed Dec. 16, 1998, in turn a divisional application of Ser. No. 08/759,714 filed Dec.6, 1996 (now U.S. Pat. No. 5,854,286). Priority is claimed from Provisional application No. 60/008361 filed Dec. 7, 1995. The subject matters of the prior applications are incorporated in their entirety herein by reference thereto.[0001]
    • BACKGROUND
  • Traditional models of schizophrenia have focused on dopaminergic systems. More recent models, however, derive from the phencyclidine (PCP, “angel dust”) model of schizophrenia (Javitt, 1987; Javitt and Zukin, 1991) and postulate that schizophrenia is associated with dysfunction or dysregulation of neurotransmission mediated at brain N-methyl-[0002] D-aspartate (NMDA)-type glutamate receptors. The PCP/NMDA model of schizophrenia raised the possibility that agents which augment NMDA receptor-mediated neurotransmission might be therapeutically beneficial in schizophrenia. The primary neurotransmitter acting at NMDA receptors is glutamate. However, NMDA receptor activity is also modulated by the amino acid glycine which binds to a selective modulatory site that is an integral component of the NMDA receptor complex. U.S. Pat. No. 5,854,286 discloses the use of orally administered glycine, in dietary quantities, for the treatment of schizophrenia.
  • Glycine is considered a full agonist at the NMDA-associated glycine binding site (McBain et al., 1989). The clinical findings with glycine detailed in the prior patents U.S. Pat. No. 5,854,286 and U.S. Pat. No. 5,837,730 applications therefore, provided the first evidence that glycine-site full agonists are effective in the treatment of schizophrenia. This concept has also recently been supported by a study utilizing D-serine (Tsai et al., 1998), an alternative glycine site full agonist (NcBain et al., 1989; Javitt et al., 1989; Kleckner and Dingledine, 1988; Wong et al., 1987; Reynolds et al., 1987), consistent with the ability of this compound to induce glycine-like behavioral effects in rodents (Tanii et al., 1994, 1991) and to penetrate into CNS following peripheral administration (Hashimoto and Oka, 1997). D-Serine, like glycine, is present in brain in high concentration and may serve as an endogenous ligand for the glycine binding site of the NMDA receptor complex (Schell et al., 1995). The use of D-serine, along with use of other agents that might substitute for glycine at the glycine site of the NMDA receptor complex, was disclosed in the above noted U.S. patents and in Provisional application No. 60/008361 filed Dec. 1, 1995. [0003]
  • Although the findings with glycine and D-serine support the use of full glycine-site agonists, others have proposed that partial agonists at the glycine site, such as the drug [0004] D-cycloserine, should be more effective than full agonists in the treatment of schizophrenia (Cordi, patent#5,187,171). Partial agonists bind to the same site as full agonists (i.e., glycine recognition site of the NMDA receptor complex), but potentiate channel opening only to a much smaller percent (typically 40-70% of the activation seen with full agonists, McBain et al., 1989). Clinical studies with D-cycloserine have provided support for the concept that partial glycine-site antagonists may be effective in the treatment of schizophrenia (reviewed in D'Souza et al., 1995), and, the degree of improvement seen in studies of D-cycloserine (reviewed in D'Souza et al., 1995) has been comparable in some circumstances to the degree of improvement observed following studies with glycine (Heresco-Levy et al., 1996; Leiderman et al., 1996 and reviewed in D'Souza et al., 1995) or D-serine (Tsai et al., 1998). No study has yet compared the effectiveness of glycine treatment to that of D-cycloserine treatment.
  • A second potential approach to augmentation of NMDA receptor-mediated neurotransmission is the administration of agents that inhibit glycine transporters in brain, thereby preventing glycine removal from active sites within CNS. It has been known for many years that the brain contains active transport systems for glycine that may regulate brain levels (Debler and Lajtha, 1987; D'Souza, 1995). More recent studies demonstrated that glycine transporters are differentially expressed in different brain region (Liu et al, 1993; Zafra et al., 1995) and may be co-localized with NMDA receptors (Smith et al., 1992). However, it has also been known for many years that extracellular glycine levels are beyond the level needed to saturate the NMDA-associated glycine binding site, making it unclear whether glycine transporters are, in fact, able to maintain subsaturating glycine levels in the immediate vicinity of NMDA receptors. This is a crucial issue in that, if glycine levels were already at or above saturating levels, additional glycine would not, on theoretical grounds, be able to stimulate NMDA functioning (Wood, 1995). [0005]
  • U.S. Pat. No. 5,837,730, to the current inventor provided the first evidence that an identified glycine transport inhibitor, glycyldodecylamide (GDA), was able to exert glycine-like, anti-PCP behavioral effects in rodents, and thus the first evidence that glycine transport inhibitors should exert glycine-like amelioration of negative and cognitive symptoms in schizophrenia. In U.S. Pat. No. 5,837,730, data were presented from a series of three compounds demonstrating appropriate rank order of potency of these compounds in producing glycine-like behavioral effects in rodents. [0006]
    • SUMMARY OF THE INVENTION
  • It is therefore unknown whether full agonists at the glycine-site as a class are more or less effective than partial agonists, and thus, it is unknown whether glycine site full-agonists as a class would be more beneficial in the treatment of persistent negative symptoms of schizophrenia. The present application provides the first direct comparison of the effectiveness of full and partial glycine agonists in the treatment of schizophrenia ([0007] Study 1, below). It demonstrates that the full agonist, glycine, produces significantly greater symptomatic improvement than the partial agonist D-cycloserine among subjects who received both treatments in placebo controlled, double blind trials. This study, therefore, provides the first evidence that substitutes for glycine at the glycine site (which are fall glycine agonists) as a class, are more effective than partial agonists. Other glycine substitutes at the glycine site include D-isomers of serine and alanine (McBain et al., 1989) and optimized derivatives thereof. Other agents such as glycineamide, threonine or glycine polypetides or glycine prodrugs are metabolized in brain to glycine, and should serve as active precursors of glycine and/or serine in the treatment of schizophrenia. Other amino acids, prodrugs or polypeptides which serve as precursors for other full glycine agonists in CNS can be employed. This may be accomplished by microencapsulation of glycine, for example using liposomes, for delivery to CNS, or by construction of polyglycine or polyserine vectors incorporating a CNS targeted moiety chosen to encourage penetration into CNS.
  • In another embodiment, the present inventor can now demonstrate that the ability of glycine transport inhibitors to reverse PCP-induced behavioral effects correlates significantly with their ability to inhibit glycine transport in vitro, supporting the discovery that such agents exert their glycine-like behavioral effects by blocking brain glycine transport. A number of glycylakylamides are tested herein (Study 2).[0008]
    • DETAILED DESCRIPTION
  • [0009] Study 1—Relative effectiveness of a glycine binding site full agonist (glycine) and partial agonist (D-cycloserine) in the treatment of schizophrenia.
  • Rationale [0010]
  • Endogenous dysfunction or dysregulation of neurotransmission mediated at NMDA-type glutamate receptors may contribute significantly to the pathophysiology of negative and cognitive symptoms of schizophrenia. NMDA receptor activation is regulated not only by glutamate but also by glycine, which mediates its action at a strychnine-insensitive binding site associated with the NMDA receptor complex. Glycinergic agents, therefore, may be therapeutically beneficial in schizophrenia. [0011]
  • Two potential agents have been suggested as potential agents for stimulation of NMDA receptor-mediated neurotransmission in schizophrenia: glycine and [0012] D-cycloserine (reviewed in D'Souza et al., 1995). Glycine is a naturally occurring amino acid and a normal dietary constituent. Glycine acts as a full agonist at the NMDA-associated glycine binding site, but must be given at large (>30 g/day) doses because of its poor permeability across the blood brain barrier. D-Cycloserine is an anti-tubercular drug that also functions as a partial agonist at the NMDA-associated glycine site. D-Cycloserine readily crosses the blood-brain barrier. However, D-cycloserine is only 40% as effective as glycine in potentiating NMDA receptor-mediated neurotransmission. Thus, at high doses, D-cycloserine may act as a functional glycine antagonist. Both glycine (the present inventor) and D-cycloserine (D'Souza et al., 1995) are reported to significantly ameliorate neuroleptic-resistant negative symptoms in schizophrenia. The relative effectiveness of these two agents, however, has not been compared.
  • METHODS [0013]
  • Seven subjects were identified who participated in each of two separate studies investigating effects of NMDA augmenting agents in schizophrenia. The first investigated effects of 0.8 g/kg/day (approx. 60 g/day) glycine. The second study investigated effects of 50 mg/day [0014] D-cycloserine. Separate informed consent was obtained for each study. Subjects met DSM-IV criteria for schizophrenia and were free of other Axis I diagnoses (including substance abuse) or concurrent medical illness. All met criteria for neuroleptic-resistance, and manifested moderate-to-severe symptoms despite continuous neuroleptic treatment for at least 3 months. Mean age of the patients upon study entry was 39.9±15.7 yrs (Table 1). Patients had been ill, on average, for 20.1±13.4 yrs. at the time of study entry. Their duration of most recent hospitalization was 8.5±7.4 yrs.
  • Both studies were conducted using a double blind, placebo-controlled crossover design. Total study length was 16 weeks. Patients underwent an initial 2 week stabilization period, following by 6 weeks of treatment with either active medication or placebo. They then underwent a 2-week washout followed by 6 weeks of crossover treatment. Antipsychotic dose was held constant throughout each trial. Symptom ratings were performed using the Positive and Negative Syndrome Scale (PANSS). One patient discontinued during week 4 of [0015] D-cycloserine treatment due to symptom exacerbation, and was not available for the placebo treatment arm.
  • Statistical analyses (two-tailed) were accomplished using the SPSS computer program. Pre-vs. post-treatment comparisons were performed using paired t-tests. Treatment vs. placebo effects were evaluated using repeated measures ANOVA. Values in text represent mean±standard deviation. [0016]
  • Results and Discussion [0017]
  • At entry into the glycine treatment study, the baseline negative symptom score for the 7 subjects was 39.0±6.6. During glycine treatment, subjects experienced an 11.3±3.6 point reduction in negative symptoms (t=8.21, df=6, p<0001), corresponding to a mean 28.5% reduction in symptoms (FIG. 1). In contrast, negative symptoms increased by 0.1±1.7 points during treatment with placebo. The treatment by time interaction was highly significant (F[1,6]=83.5, p<0.001). Positive symptoms did not change significantly from beginning (25.7±7.0 points) to end (22.0±4.0 points) of glycine treatment. However, a significant, 13.0±7.7 point change in general psychopathology from 56.0±19.4 to 43.0±13.8 points was observed (t=4.44, df=6, p<0.005). This reduction corresponded to a 23.2% decrease in symptoms. [0018]
  • Following completion of the double blind glycine treatment study, subjects included in this report were treated with antipsychotics alone for a mean duration of 15.6±5.9 mo. (range: 6-23 mo.) before being entered into the [0019] D-cycloserine study. The mean negative symptom score for these subjects upon entry into the D-cycloserine study, 39.0±7.8, was highly similar to the score that had been observed prior to glycine treatment. Medications and doses used during the D-cycloserine trial were similar to those used during the prior glycine trial (Table 1).
  • During [0020] D-cyloserine treatment, subjects experienced a significant, 3.6±3.7 point reduction in negative symptoms (t=2.56, p<.05), corresponding to a mean 9.2% decrease in symptoms. In contrast, the degree of negative symptom reduction during placebo treatment for these subjects, 1.0±3.1 points , was not significant. However, the treatment by time interaction was not significant (F[1,5]=1.87, p=0.23). Positive symptoms and general psychopathology scores did not change significantly during treatment with either D-cycloserine or placebo.
  • In order to assess relative effectiveness of glycine and [0021] D-cycloserine for treatment of negative symptoms in these subjects, negative symptom change scores were compared across the two trials. The degree of reduction in negative symptoms observed during glycine treatment was 3-fold greater than that observed during D-cycloserine treatment. The difference was highly significant (t=8.2, df=6, p<0.0001). These data provide the first direct comparison of effects of glycine and D-cycloserine in the same group of patients, and the first demonstration that the full agonist glycine is significantly more effective in the treatment of negative symptoms of schizophrenia than the partial agonist D-cycloserine. The finding that the full agonist, glycine, is superior to the partial agonist D-cycloserine suggests that other full agonists of the glycine site (or precursors thereof) should also be therapeutically beneficial in schizophrenia. Other potential agents to be used would include D-serine, D-alanine, glycineamide, threonine and polypeptide precursors of such compounds.
    TABLE 1
    Demographic and treatment characteristics of study patients
    Glycine study D-Cycloserine study
    Subject Age Gender Medication Dose (mg/day) Medication Dose (mg/day)
    1 57 M thioridazine 250 thioridazine 100
    2 44 M clozapine 200 clozapine 200
    3 24 M thioridazine  50 thioridazine 100
    4 49 M clozapine 400 clozapine 400
    5 25 M clozapine 450 risperidone  6
    6 63 F chlorpormazine 300 haloperidol  40
    7 30 F clozapine 350 clozapine 400
  • Experiment #2—Inhibition of PCP-induced hyperactivity by glycine-transport gonists [0022]
  • Rationale [0023]
  • Earlier double blind, placebo-controlled trials of glycine in schizophrenia support the that NMDA augmenting agents will be beneficial in the treatment of schizophrenia. See U.S. Pat. No. 5,854,286. The clinical utility of this agent is limited, however, by the relatively large doses that are required to significantly elevate CNS glycine levels (Toth and Lajtha, 1986; D'Souza et al., 1995). The large doses are required because glycine permeates across the blood-brain barrier slowly by passive diffusion, and, once in the CNS, is sequestered intracellularly by glycine transporters. Two families of glycine transporters have been identified. glycine type 2 (GLYT2) transporters are co-localized with inhibitory (strychnine-sensitive) glycine receptors in hindbrain and spinal cord and maintain low glycine levels within the synaptic cleft in those brain regions. In contrast, type 1 transporters (GLYT1) are co-localized with NMDA receptors in forebrain and hippocampus, and may serve to maintain low intrasynaptic glycine levels specifically in the local region around NMDA receptors. It is possible, therefore, that inhibition of GLYT1 transporters would lead to elevations of glycine levels in the immediate vicinity of NMDA receptors and augmentation of NMDA receptor-mediated neurotransmission without requiring administration of exogenous glycine. Support for such a hypothesis comes from a recent study in which co-expression of GLYT1 transporters along with NMDA receptors in Xenopus oocytes led to significant inhibition of NMDA receptor responsiveness (Supplison and Bergman, 1996). Blockade of GLYT1 transporters would thus theoretically be expected to exert an opposite effect. The use of glycine transport blockers to augment NMDA receptor-mediated neurotransmission would be analogous to the use of noradrenaline/serotonin reuptake inhibitors (rather than precursors such as tyrosine or tryptophan) to enhance monoaminergic neurotransmission. [0024]
  • In early preclinical studies investigating effects of glycine on PCP-induced hyperactivity, it was noted that a specific glycine derivative, GDA, was significantly more potent than glycine itself in reversing PCP-induced hyperactivity (Toth et al., 1986). Although the mechanism of action of GDA was unknown at the time of those initial studies, more recent research has demonstrated that GDA acts as a glycine transport inhibitor at doses similar to those used in behavioral studies (U.S. Pat. No. 5,837,730); Javitt and Frusciante, 1997; Javitt et al., 1997). To the extent that the behavioral effects of GDA are due to its inhibition of glycine transport, the ability of GDA to antagonize PCP-induced hyperactivity supports the concept that glycine transport inhibitors, particularly those acting at GLYT1 transporters, may be useful in the treatment of schizophrenia. However, because GDA may have idiosyncratic effects unrelated to its effects at the glycine transport site, it is important to test additional compounds with known affinity for glycine transporters. For this study, several novel GDA-related compounds were synthesized and their effects on PCP-induced hyperactivity and in vitro glycine transport were characterized. These compounds were structurally similar to GDA, but differed in the length of the carbon sidechain that was joined to the glycine backbone via the amide linkage. The length of carbon chain varied from 6 to 13 carbon atoms. The 6-carbon analog (G6A) was found in one early study not to significantly inhibit PCP-induced hyperactivity (Toth et al., 1986). The other agents (G8A, G10A, G11A and G13A) had not been synthesized previously. [0025]
  • Methods [0026]
  • Glycinearnide derivatives were synthesized in house according to the approach of Toth et al (1986). The specific agents used for study were glycylhexylamide (G6A), glycyloctylamide (G8A), glycyldecylamide (G10A), glycylundecylamide (G11A) and glycyltriscadecylamide (G13A). [0027]
  • Behavioral studies were performed using BALB/c mice (25 g) of either sex. Rodent activity was monitored using a photocell-based activity meter (Columbus Instruments Auto-Track System, Columbus, Ohio). Animals were placed in test cages and allowed to accommodate overnight. On the day of experiment, animals, in their home cages, were placed on the activity monitors and baseline activity was monitored for 20 min., after which time animals were pretreated with either saline or a specified glycineamide derivative ( 0.1 g/kg i.p.). 30 min. after pretreatment, animals were injected with either PCP (5 mg/kg i.p.) or amphetamine (5 mg/kg s.c.). Activity was then monitored for an additional 90 minutes. For statistical analyses, summed activity over the 90 min. following PCP/amphetamine injection was used as a measure of drug-induced hyperactivity. [0028]
  • Synaptosomal P[0029] 2 fractions were prepared from cerebral cortex+hippocampus of Sprague-Dawley rats (200-250 g). Brain tissue was homogenized in 0.32 M sucrose in Tris-HCl buffer (pH 7.4), and centrifuged at 1,000×g for 10 min at 4° C. in a Sorvall 5C centrifuge. The supernatant was then centrifuged at 14,000×g for 10 min and the pellet resuspended in artificial CSF having the following composition (mM): NaCl, 125; KCl, 3; MgSO4, 1.2; CaCl2, 1.2; NaH2PO4, 1; NaHCO3, 22; glucose, 10. Homogenate was aerated with 95% 02/5% CO2 until use. 1 ml aliquots of homogenate were preincubated with specific concentrations of glycineamide derivatives, following which incubation was initiated by the addition of 10 μl of 10 μM [3H]glycine (DuPont/NEN or Sigma, spec. act.≈45 Ci/mmol) to obtain a final concentration of 100 nM. Nonspecific binding was determined in the presence of 10 mM sarcosine. Following 5 min, incubation was terminated by filtration under reduced pressure using a Brandel 24-well cell harvester and Whatman GF-B filters. Radioactivity was determined by scintillation counter with approximate efficiency of 50%.
  • Results [0030]
  • In prior studies, GDA has been found to inhibit PCP-induced hyperactivity at doses of 50-200 mg/kg i.p. For the present study, an initial experiment evaluated the specificity of the GDA effect. Rats were pre-treated with GDA (50 mg/kg i.p.) after which they received either PCP (5 mg/kg i.p.) or amphetamine (5 mg/kg i.p.). Both PCP and amphetamine induced significant levels of hyperactivity. Pretreatment with GDA did not significantly affect basal activity. However, GDA significantly reduced the degree of hyperactivity induced by PCP (t=4.09, p<0.001) (FIG. 2). In contrast, the level of hyperactivity induced by amphetamine was not significantly altered (t=0.59, p>0.5). GDA-induced inhibition of PCP-induced hyperactivity was significantly dose-dependent with 50 mg/kg GDA inducing a reduction of hyperactivity to below 70% of control (PCP alone) levels, and 100 mg/kg GDA inducing a reduction to below 50% of control (t=5.04, p<0.001) (FIG. 3). [0031]
  • Because it was assumed that the majority of glycineamide derivatives tested would be less potent that GDA in reversing PCP-induced hyperactivity, a dose of 100 mg/kg i.p. was chosen for comparative testing. As has been reported previously (Toth et al., 1986), glycylhexylamide (G6A) did not significantly inhibit PCP-induced hyperactivity. Significant reductions in activity were, however, observed following pretreatment with G10A, GDA, and G13A, with the degree of reduction increasing with increasing length of the carbon sidechain (FIG. 3). [0032]
  • The potency with which the identified glycineamide derivatives inhibited glycine transport in vitro was analyzed using a synaptosomal assay system. All agents tested induced significant, dose-dependent inhibition of synaptosomal sarcosine-sensitive glycine uptake (FIG. 4). Agents with longer side chains showed greater potency for inhibition of glycine transport with IC50 values in the low micromolar range, whereas shorter chain derivatives showed IC50 values in the low to mid millimolar range. In order to compare the potency of these agents at a concentration relevant to the dose used for behavioral testing, all agents were re-tested for inhibitory potency at a single fixed concentration of 100 μg/ml. Significant variation was seen across compounds, with GDA, (t=18.6, p<0.0001), G13A (t=15.3, p<0.0001), G11A (t=6.79, p<.001) and G10A (t=4.64, p<.01) leading to significant inhibition of GLYT1-mediated transport, G8A having no significant effect (t=1.37, p>.2), and G6A leading to significant potentiation of transport (t=4.2, p<0.01). The potency with which the glycineamide derivatives inhibited GLYT1-mediated synaptosomal glycine transport correlated significantly (p<0.05) with their potency in antagonizing PCP-induced hyperactivity (FIG. 5). [0033]
  • Other agents which should be useful for treating schizophrenia through inhibition of glycine transport include other glycylakylamides in which the alkyl group contains 3 to 30 carbon atoms, and structures containing branched, cyclic or polycyclic side chains. [0034]
    • REFERENCES
  • Davis K L, Kahn R S, Ko G, Davidson M (1991): Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474-1486. [0035]
  • Debler E A, Lajtha A (1987): High-affinity transport of n-aminobutyric acid, glycine, taurine, L-aspartic acid, and L-glutamatic acid in synaptosomal (P2) tissue: a kinetic and substrate specificity analysis. J Neurochem 48:1851-6. [0036]
  • D'Souza D C, Chamey D, Krystal J (1995): Glycine site agonists of the NMDA receptor: a review. CNS Drug Revs 1:227-260. [0037]
  • Hashimoto A, Oka T (1997): Free D-aspartate and D-serine in the mammalian brain and periphery. Prog. Neurobiol 52:325-353. [0038]
  • Heresco-Levy U, Javitt D C, Irrilov M, Mordel C, Horowitz A, Kelly D (1996): Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610-617. [0039]
  • Javitt D C, Sershen H, Hashim A, Lajtha A (1997): Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake antagonist glycyldodecylamide. Neuropsychopharmacol 17:202-204. [0040]
  • Javitt D C, Frusciante M J. (1997): Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: Implications for schizophrenia and substance abuse. Psychopharmacol. 129: 96-98. [0041]
  • Javitt D C, Zylberman I, Zukin S R, Heresco-Levy U, Lindenmayer JP (1994): Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236. [0042]
  • Javitt D C, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-8. [0043]
  • Javitt D C, Zukin S R (1989): Interaction of [[0044] 3H]MK-801 with multiple states of the N-methyl-D-aspartate receptor complex of rat brain. Proc. Nat. Acad. Sci. USA 86:740-744.
  • Javitt D C (1987): Negative schizophrenic symptomatology and the phencyclidine (PCP) model of schizophrenia. Hill J Psychiat 9:12-35. [0045]
  • Kleckner N W, Dingledine R (1988): Requirement for glycine in the activation of NMDA-receptors expressed in Xenopus ooctyes. Science 241:835-837. [0046]
  • Leiderman E, Zylberman I, Javitt D C, Zukin S R, Cooper T B. Effect of high-dose oral glycine on serum levels and negative symptoms in schizophrenia. Biol. Psychiatry, in press. [0047]
  • Liu Q R, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N (1993): Cloning and expression of spinal cord- and brain-specific glycine transporter with novel structural features. J Biol Chem 268:22802-8. [0048]
  • Matsui T, Sekiguchi M, Hashimoto A, Tomita V, Nishikawa T, Wada K (1995) Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. J Neurochem. 65:454-458. [0049]
  • McBain C J, Kleckner N W, Wyrick S, Dingledine R (1989): Structural requirements for the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Mol Pharmacol 36:556-565. [0050]
  • Reynold I J, Murphy S N, Miller R J (1987): 3H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc. Natl. Acad. Sci. USA 84:7744-7748. [0051]
  • Schell M J, Molliver M E, Snyder S H (1995). D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc. Natl. Acad. Sci. USA 92:3948-3952. [0052]
  • Smith K E, Borden L A, Hartig P R, Branchek T, Weinshank R L (1992): Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8:927-35. [0053]
  • Supplisson S, Bergman C (1997): Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci 17:4580-90. [0054]
  • Tanii Y, Nishikawa T, Hashimoto A, Takahashi K (1991): Stereoselective inhibition by D- and L-alanine of phencyclidine-induced locomotor stimulation in the rat. Brain Res 563:281-284. [0055]
  • Tanii Y, Hishikawa T, Hashimoto A, Takahashi K (1994): Stereoselective antagonism by enantiomers of alanine an d-serine of phencyclidine-induced hyperactivity, stereotypy and ataxia. J. Pharmacol. Exp. Ther. 269:1040-1048. [0056]
  • Tsai G, Yang P, Chung L-C, Lange N, Coyle J T (1998): D-serine in the treatment of schizophrenia. Biol. Psychiatry 44:1081-1089. [0057]
  • Wood P L (1995): The co-agonist concept: is the NMDA-associated glycine receptor saturated in vivo? Life Sci 57:301-10. [0058]
  • Wong E H, Knight A R, Ransom R (1987) Glycine modulates [3H]MK-801 binding to the NMDA receptor in rat brain. Eur J Pharmacol 142:487-8. [0059]
  • Zafra F, Aragon C, Olivares L, Danbolt N C, Gimenez C, Storm-Mathisen J (1995): Glycine transporters are differentially expressed among CNS cells. J Neurosci 15:3952-69 [0060]
  • Variations of the invention will be apparent to the skilled artisan. [0061]

Claims (8)

What is claimed:
1. A process for treating a human patient having a psychosis which comprises administering to said human a substitute for glycine at the glycine-site or a precursor of said substitute or a glycine precursor, in an amount sufficient to potentiate NMDA receptor-mediated neurotransmission.
2. The process of claim 1 wherein the treatment increases the patient's glycine CNS level.
3. The process of claim 1 wherein, D-serine or D-alanine is administered.
4. The process of claim 1 wherein an amino acid, polypeptide or prodrug which functions as a precursor of glycine synthesis in the CNS is administered.
5. The process of claim 1 wherein an amino acid, polypeptide or prodrug which functions as a precursor of D-serine synthesis in the CNS is administered.
6. The process of claim 1 wherein the psychosis is schizophrenia.
7. The process of claim 1 wherein a substitute for glycine is administered.
8. The process of claim 1 wherein a precursor of a substitute for glycine is administered.
US10/059,362 1995-12-07 2002-01-31 Glycine substitutes and precursors for treating a psychosis Abandoned US20020161048A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/059,362 US20020161048A1 (en) 1995-12-07 2002-01-31 Glycine substitutes and precursors for treating a psychosis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US836195P 1995-12-07 1995-12-07
US08/759,714 US5854286A (en) 1995-12-07 1996-12-06 Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors
US09/212,273 US6162827A (en) 1995-12-07 1998-12-16 Treatment of negative and cognitive symptoms of schizophrenia with D-serine
US09/320,446 US6355681B2 (en) 1995-12-07 1999-05-27 Glycine substitutes and precursors for treating a psychosis
US10/059,362 US20020161048A1 (en) 1995-12-07 2002-01-31 Glycine substitutes and precursors for treating a psychosis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/320,446 Continuation US6355681B2 (en) 1995-12-07 1999-05-27 Glycine substitutes and precursors for treating a psychosis

Publications (1)

Publication Number Publication Date
US20020161048A1 true US20020161048A1 (en) 2002-10-31

Family

ID=27358591

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/320,446 Expired - Fee Related US6355681B2 (en) 1995-12-07 1999-05-27 Glycine substitutes and precursors for treating a psychosis
US10/059,362 Abandoned US20020161048A1 (en) 1995-12-07 2002-01-31 Glycine substitutes and precursors for treating a psychosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/320,446 Expired - Fee Related US6355681B2 (en) 1995-12-07 1999-05-27 Glycine substitutes and precursors for treating a psychosis

Country Status (1)

Country Link
US (2) US6355681B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667297B2 (en) 1998-04-14 2003-12-23 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US20080051458A1 (en) * 2006-07-28 2008-02-28 Xuedong Dai Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
US20090176715A1 (en) * 2008-01-09 2009-07-09 Amino Acids Solutions Inc. Pharmaceutical Compositions and Methods Utilizing a D-Amino Acid

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US7750030B2 (en) * 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
RU2006127475A (en) 2003-12-29 2008-02-10 Джейсон МАКДЭВИТТ (US) COMPOSITIONS AND METHODS OF TREATMENT OF RETRIDGING MEDICAL CONDITIONS
JP4405277B2 (en) * 2004-02-16 2010-01-27 株式会社日立製作所 Disk controller
US7467238B2 (en) * 2004-02-10 2008-12-16 Hitachi, Ltd. Disk controller and storage system
AU2006235400A1 (en) * 2005-04-11 2006-10-19 Yale University Method of treating schizophrenia prodrome
US20110263968A1 (en) * 2008-11-04 2011-10-27 Mclean Hospital Corporation Drug-Enhanced Neurofeedback

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015740A (en) * 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US5051448A (en) * 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US5468763A (en) * 1987-12-01 1995-11-21 G. D. Searle & Co. Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5837730A (en) * 1995-12-07 1998-11-17 Javitt; Daniel C. Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
JP2757960B2 (en) * 1988-10-17 1998-05-25 サントリー株式会社 (2R, 3S, 4S) -α- (carboxycyclopropyl) glycine
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5179085A (en) * 1989-03-15 1993-01-12 Warner-Lambert Company N-substituted α-amino acids and derivatives thereof having pharmaceutical activity
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
AU679432B2 (en) 1991-11-12 1997-07-03 H. Lundbeck A/S DNA encoding a glycine transporter and uses thereof
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051448A (en) * 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US5468763A (en) * 1987-12-01 1995-11-21 G. D. Searle & Co. Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5015740A (en) * 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US5837730A (en) * 1995-12-07 1998-11-17 Javitt; Daniel C. Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
US5854286A (en) * 1995-12-07 1998-12-29 Daniel C. Javitt Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors
US6162827A (en) * 1995-12-07 2000-12-19 Daniel Javitt Treatment of negative and cognitive symptoms of schizophrenia with D-serine
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667297B2 (en) 1998-04-14 2003-12-23 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US20040092530A1 (en) * 1998-04-14 2004-05-13 The General Hospital Corporation, A Massachusetts Corporation Methods for treating neuropsychiatric disorders
US20050250851A1 (en) * 1998-04-14 2005-11-10 The General Hospital Corporation, A Massachusetts Corporation Methods for treating neuropsychiatric disorders
US6974821B2 (en) 1998-04-14 2005-12-13 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US7704978B2 (en) 1998-04-14 2010-04-27 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US20080051458A1 (en) * 2006-07-28 2008-02-28 Xuedong Dai Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
US7531572B2 (en) 2006-07-28 2009-05-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
US20090192225A1 (en) * 2006-07-28 2009-07-30 Xenoport, Inc. Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use
US7799829B2 (en) 2006-07-28 2010-09-21 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
US10265278B2 (en) 2008-01-08 2019-04-23 Aas, Llc Pharmaceutical compositions and methods utilizing a D-amino acid
US20090176715A1 (en) * 2008-01-09 2009-07-09 Amino Acids Solutions Inc. Pharmaceutical Compositions and Methods Utilizing a D-Amino Acid

Also Published As

Publication number Publication date
US6355681B2 (en) 2002-03-12
US20020013364A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
US5837730A (en) Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
Kohl et al. The NMDA receptor complex: a promising target for novel antiepileptic strategies
Löscher Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy
Goff et al. Glutamate in schizophrenia: clinical and research implications
Paz et al. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology
Heresco-Levy et al. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes
Hauser Levodopa: past, present, and future
Harkin et al. Nitric oxide synthase inhibitors have antidepressant-like properties in mice: 1. Acute treatments are active in the forced swim test
Poleszak et al. NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice
US20020183390A1 (en) D-serine transport antagonist for treating psychosis
Shen et al. Glycine transporter 1 is a target for the treatment of epilepsy
SA01210655B1 (en) Pyrrolidineacetamide Derivatives alone or in combination for the treatment of disorders of the central nervous system.
US6355681B2 (en) Glycine substitutes and precursors for treating a psychosis
JP5266042B2 (en) Treatment method for schizophrenia precursor
Niedzielska-Andres et al. Cocaine use disorder: a look at metabotropic glutamate receptors and glutamate transporters
Rousseaux A review of glutamate receptors I: current understanding of their biology
Tchekalarova et al. The role of the melatoninergic system in epilepsy and comorbid psychiatric disorders
US20170172957A1 (en) D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders
Lumley et al. Reduced isolation-induced aggressiveness in mice following NAALADase inhibition
Bespalov et al. Prolongation of morphine analgesia by competitive NMDA receptor antagonist D-CPPene (SDZ EAA 494) in rats
Amaral et al. Targeting the NMDA receptor for fear-related disorders
Kinney et al. Glycine site modulators and glycine transporter-1 inhibitors as novel therapeutic targets for the treatment of schizophrenia
WO1999063989A1 (en) Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia
CA2239624C (en) Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
Goff et al. Glutamatergic augmentation strategies for cognitive impairment in schizophrenia

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION